CD8A and hepatocellular carcinoma: This has been further strengthened by the study of Duffy et al., 2017, where they reported the activation of the immune system through checkpoint inhibitors and accumulation of intratumoral CD8+ T cells following RF ablation, thus demonstrating the synergism of combined use of checkpoint inhibitor tremelimumab and ablation in aggressive hepatocellular carcinomas [67].